ENTRY       D11559                      Drug
NAME        Onasemnogene abeparvovec (USAN/INN);
            Onasemnogene abeparvovec-xioi;
            Zolgensma (TN)
PRODUCT     ZOLGENSMA (Novartis Gene Therapies)
REMARK      Therapeutic category: 4900
            ATC code: M09AX09
            Product: D11559<US>
EFFICACY    Spinal muscular atrophy treatment
  DISEASE   Spinal muscular atrophy (bi-allelic SMN1 mutations) [DS:H00455]
  TYPE      Gene therapy product
COMMENT     Recombinant AAV9-based gene therapy designed to deliver a copy of the gene encoding the human SMN protein
TARGET      SMN1 [HSA:6606] [KO:K13129]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             M MUSCULO-SKELETAL SYSTEM
              M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
               M09A OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
                M09AX Other drugs for disorders of the musculo-skeletal system
                 M09AX09 Onasemnogene abeparvovec
                  D11559  Onasemnogene abeparvovec (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Onasemnogene abeparvovec
               D11559  Onasemnogene abeparvovec (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              49  Other agents affecting cellular function
               490  Other agents affecting cellular function
                4900  Other agents affecting cellular function
                 D11559  Onasemnogene abeparvovec (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Signaling molecules
               Spliceosome
                SMN1
                 D11559  Onasemnogene abeparvovec (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             Cellular and gene therapy products
              D11559
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11559
            New drug approvals in Japan [br08318.html]
             Cellular and gene therapy products
              D11559
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11559
            Pharmacogenomic biomarkers [br08341.html]
             Germline mutations in genetic disorder treatments
              D11559
DBLINKS     CAS: 1922968-73-7
            PubChem: 384585535
///
